Navigation Links
FDA Approved Diabetes Drug Despite Hints at Cancer Risk
Date:2/18/2010

Rat studies suggest Victoza could spur rare thyroid tumor, but experts say effects in humans are unclear

THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food and Drug Administration is defending its decision in late January to approve a new diabetes drug, Victoza (liraglutide), even though animal studies suggest it might increase the risk for a rare thyroid cancer.

Victoza, among a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, is meant to be used along with diet and exercise to control blood sugar by helping the pancreas make more insulin after a person eats.

FDA officials explained the agency's stance on the drug in a Perspective article published online Feb. 17 in the New England Journal of Medicine.

"The relevance of the animal findings to people is unknown," said FDA spokeswoman Dr. Karen Mahoney. "The type of tumor of concern in people is medullary thyroid cancer, which is a very rare tumor that one cannot expect to be detected in a clinical trial."

No one treated with Victoza in the clinical trial that led to the drug's approval developed this type of cancer, she noted.

However, studies in rats showed that some animals treated with Victoza did develop thyroid tumors. "Some of these tumors were cancerous," Mahoney said. "In rats, cancers were also observed in untreated animals."

The cancer finding in treated rats, compared with the untreated group, was not considered significantly different, statistically, except among male rats that received an eight-fold higher drug exposure than what humans would receive at even the maximum proposed dose, Mahoney said.

"The life span of the animals in these two studies was not affected by liraglutide treatment," she added.

The drug also carries a slight increased risk of pancreatitis, which is not uncommon in diabetics. A common side effect of Victoza is nausea and vomiting, which can also be a sign of pancreatitis, and people taking the drug should be evaluated for that possibility, according to the FDA.

All drugs are associated with risks, Mahoney noted, and Victoza does bring benefit to those taking it.

"Liraglutide is an effective anti-diabetic drug, and controlling blood sugar in patients not adequately treated with other available therapies is very important in preventing the long-term complications of diabetes," she said.

"For this reason, FDA considered the benefits to outweigh the risks, provided that prescribers carefully read the labeling and recommendations for use and select their patient appropriately for liraglutide use," Mahoney said.

She noted that Victoza has one advantage over its only other competitor in this class of drugs, Byetta. Byetta is administered as a twice-daily injection, whereas Victoza is a once-daily injection, Mahoney noted.

The agency is requiring that a medication guide be provided with every prescription filled for Victoza.

"Prescribers will need to carefully review the package insert before considering liraglutide for their patients," Mahoney said. "Patients need to read the medication guide. If after reading the medication guide the patient still has questions or concerns, these need to be raised with the health-care provider."

Two diabetes experts agreed that Victoza could be an important addition to the treatment of type 2 diabetes.

Dr. Joel Zonszein, a professor of clinical medicine in the Clinical Diabetes Center at the Albert Einstein College of Medicine in New York City, said that any controversy over cancer risk is "much to-do about nothing."

Although this rare thyroid cancer can be seen in rodents, "there is no evidence that this is the case in humans," he said. "It is not good to create panic for something that has a very low risk."

According to Zonszein, people should be more concerned about having untreated diabetes than about any unproven risks tied to Victoza.

Dr. Luz Marina Prieto, an assistant professor of clinical medicine at the Diabetes Research Institute of the University of Miami Miller School of Medicine, agreed. She said that Victoza "has given the benefit of better glycemic control and less progression of complications."

Prieto said the drug allows doctors to get a patient's diabetes under control before irreversible complications, such as kidney problems, set in.

The drug "produces weight loss, which is excellent, better glucose control and decreases the possibility of insulin resistance," she said.

Victoza is used in combination with other diabetes medications, such as metformin, and should also be given in conjunction with healthy changes in lifestyle, Prieto said.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more on diabetes.



SOURCES: Karen Mahoney, M.D., spokeswoman, U.S. Food and Drug Administration, Silver Spring, Md.; Luz Marina Prieto, M.D., assistant professor, clinical medicine, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami; Joel Zonszein, M.D., professor, clinical medicine, Clinical Diabetes Center, Albert Einstein College of Medicine, Montefiore Medical Center, New York City; Feb. 17, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
9. Pennsylvania American Waters Rate Case Approved
10. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
11. Hiemstra Approved to Manufacture Medical Devices in New CER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... weight management program at Women’s Excellence will help patients lose weight and keep ... exam. The specialists at Women's Excellence will measure BMI, body fat composition, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is ... complicated and require expert user knowledge. In a live webinar on April 11th ... simplified, yet highly accurate, determination of sodium. , It has long been known ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: